Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)

NCT00446849 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00446849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00446849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)
Lead sponsor
Shire
Phase
Phase 4
Overall status
Completed
Start date
May 1, 2007
Completion date
August 17, 2009
Enrollment
290 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis